Company profile

Zymergen

Zymergen raised $883 million across major rounds, including a $300M Series D in 2020 backed by Baillie Gifford, DCVC, and SoftBank Vision Fund. Its earlier $406M Series C in 2018 also included investors like Two Sigma Ventures, DFJ, and Goldman Sachs Investment Partners. Zymergen’s Series B, totaling $130M, came from DCVC, SoftBank Capital, and Iconiq Capital, propelling the company to unicorn status within six years. With a strong investor base and advanced bio-manufacturing capabilities, Zymergen became one of the most heavily funded synthetic biology players prior to its acquisition.

Back to profiles

Quick facts

Total funding: $883 million

Notable investors

Baillie Gifford
DCVC
SoftBank Vision Fund

Reach buyers like Zymergen on TexAu

TexAu helps go-to-market teams find, enrich, and reach companies that match this profile. Pick the path that fits how you work.

Find companies like Zymergen
Build a list by industry, headcount, funding stage, or technographics. Get verified emails and direct dials.
Start a free workspace
Enrich your CRM with company data
Push funding, headcount, hiring signals, and tech stack into HubSpot, Salesforce, or a spreadsheet. Waterfall enrichment.
See how the waterfall works
Run it on a schedule
Refresh the list weekly, score new accounts as they land, and push the ones that fit to Smartlead, Instantly, Lemlist, HeyReach, or Apollo Sequences.
See how schedulers work

Reach buyers like Zymergen.

The 14-day trial ships every feature, no card required.

Start free →